England’s HTA Body To Revamp Product Selection Processes
New Unified Panel Will Identify Technologies For Guidance Development
Proposals from NICE now under consultation are intended to boost the health technology assessment body’s efficiency, improve transparency and governance, and raise the quality of its guidance.
You may also be interested in...
Companies selling gene therapies and other high-cost, long-term treatments may be disappointed but unsurprised to learn that NICE will not immediately introduce any change to discount rates, which are used in health technology appraisals to better understand the long-term costs and benefits.
The latest initiative under the UK’s Life Sciences Vision is intended to fund the development of innovative treatments while saving the National Health Service “millions of pounds.”
New, more flexible regulatory approaches will be needed to deal with the integrated therapies coming through company pipelines, and the European Medicines Agency should play a “key orchestrating role” in smoothing the way, says Sabine Atzor, Roche’s head of EU regulatory policies.